Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

EU backs changing monkeypox vaccine injection method to boost supply

European countries could stretch out limited supplies of the monkeypox vaccine by administering smaller doses of the shot, the European Medicines Agency (EMA) said on Friday.

Reuters

EU regulator OKs plan to increase monkeypox vaccine supplies

The European Medicines Agency said a smaller dose of the monkeypox vaccine appears to still be effective and can be used to stretch the current supply by five times, echoing a recommendation made earlier this month by the U.S. Food and Drug Administration

The Independent UK

Illinois Senate President Don Harmon, other pols keep taking money from pharma companies implicated in opioid crisis

The Oak Park Democrat continues to accept campaign money from Johnson & Johnson, 1 of 4 companies paying $26 billion to settle suits accusing them of fueling the crisis. He’s not the only Illinois official doing so.

Chicago Sun-Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Drug trade thrives in darknet

Drug traffickers have gone hi-tech and are using dark web, social media and crypto currency to carry on their activities clandestinely, reveals a police investigation following a drug bust

The Hindu

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

Benzinga

Awakn's Second Licensing Partnership Agreement In A Week, This Time In Canada: Ketamine For Pain Comorbidities

Psychedelics therapeutics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed what constitutes its first licensing partnership deal in Canada.

Benzinga

Clinical Grade 'LaNeo' MDMA Completes Release Testing And Is Ready For Export In Several Dosages

PharmAla Biotech Holdings Inc, the biotech company producing MDXX class molecules has released a large-scale batch of its proprietary MDMA API, “Laneo,” becoming the first publicly-traded venture to produce the drug within Good Manufacturing Processes (GMP) in such a major amount.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

1 Stock You Shouldn't Sell No Matter What

Renowned biopharmaceutical company AbbVie (ABBV) continued its business momentum in the second quarter with considerable progress for its new products and indications. Moreover, the company is well-positioned to benefit from significant advances across its pipeline. Given its diversified business model, strong financials, high profitability, discounted valuation, and solid growth prospects,…

StockNews.com

2 Pharma Stocks to Keep Your Portfolio Healthy This Fall

Despite the market volatility and odds of a recession, the pharma industry is well-positioned to grow due to the aging global population and the increasing chronic diseases. Therefore, investing in quality pharma stocks Pfizer (PFE) and Merck & Co. (MRK) could be wise. Read more.

StockNews.com

Supreme Court hears plea to monitor drug pricing

Petitioner cites case of Dolo 650, says any dosage beyond 500 mg is outside regulation

The Hindu

Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with e

Benzinga

Endo, a PA opioid maker, files for bankruptcy with billions in debt

Endo International, one of the nation's larger opioid makers and with U.S. headquarters in Malvern, filed for bankruptcy protection in Manhattan on Tuesday, beset by $9.5 billion in total debt and threatened by thousands of opioid lawsuits.

The Philadelphia Inquirer

If You Invested $1,000 In Johnson & Johnson Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Hypocrisy All Around: Pfizer, NFL Are Hidden Sponsors Of Anti-Drug Group Fighting Against Cannabis Legalization

The Community Anti-Drug Coalitions of America (CADCA), which is fighting against federal cannabis legalization, recently removed a page on its website disclosing its partners.

Salon

Ron Johnson goes to bat for Big Pharma

Johnson worried that bill allowing Medicare to negotiate costs is "punishing the pharmaceutical industry"

Benzinga

BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S.

AAP

CSL FY net profit dips to $A3.2bln

Blood products and vaccines supplier CSL has reported a six per cent fall in annual profit and is tipping a slightly better earnings performance in 2022/23.

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

Biden signs sweeping climate, health care, tax bill into law

The legislation has been a year in the making, with tense negotiations leading to a narrower spending package that focuses on climate investments and health care costs.

WEKU

Millions of Americans will soon be able to buy hearing aids without a prescription

A new FDA rule allows adults with perceived mild to moderate hearing loss to buy hearing aids over the counter. Efforts to make them more affordable and accessible have been in the works for years.

StockNews.com

2 Pharma Stocks That'll Make You Rich in the Long Term

Substantial investments in R&D, an aging population, and growing demand for advanced drugs to treat chronic diseases should drive the pharmaceutical industry’s growth. Therefore, investing in fundamentally strong and dividend-paying pharma stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) could help dodge the current market volatility and generate substantial…

Input

Martin Shkreli claims porn virus hack cost him $450K in crypto tokens

A suspicious dump of Shkreli's newly created crypto token may have been the result of malware disguised as porn.

The Guardian - UK

No plans for UK to order more supplies of AstraZeneca Covid vaccine

JCVI says mRNA vaccines such as the Pfizer and Moderna jabs are the most effective for UK booster programme

StockNews.com

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

This Biotech Breakout Star is Our Growth Stock of the Week

Vertex Pharmaceuticals (VRTX) is a high-quality biotech stock that is quite cheap with impressive growth prospects. Read on to find out why it’s our growth stock of the week….

1 … 136 137 138 139

People

Dipanjan BanchurSince

722 stories

Pat Nabong

621 stories

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.